SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chow, Pierce K. H. | - |
dc.contributor.author | Gandhi, Mihir | - |
dc.contributor.author | Tan, Say-Beng | - |
dc.contributor.author | Khin, Maung Win | - |
dc.contributor.author | Khasbazar, Ariunaa | - |
dc.contributor.author | Ong, Janus | - |
dc.contributor.author | Choo, Su Pin | - |
dc.contributor.author | Cheow, Peng Chung | - |
dc.contributor.author | Chotipanich, Chanisa | - |
dc.contributor.author | Lim, Kieron | - |
dc.contributor.author | Lesmana, Laurentius A. | - |
dc.contributor.author | Manuaba, Tjakra W. | - |
dc.contributor.author | Yoong, Boon Koon | - |
dc.contributor.author | Raj, Aloysius | - |
dc.contributor.author | Law, Chiong Soon | - |
dc.contributor.author | Cua, Ian H. Y. | - |
dc.contributor.author | Lobo, Rolley R. | - |
dc.contributor.author | Teh, Catherine S. C. | - |
dc.contributor.author | Kim, Yun Hwan | - |
dc.contributor.author | Jong, Yun Won | - |
dc.contributor.author | Han, Ho-Seong | - |
dc.contributor.author | Bae, Si-Hyun | - |
dc.contributor.author | Yoon, Hyun-Ki | - |
dc.contributor.author | Lee, Rheun-Chuan | - |
dc.contributor.author | Hung, Chien-Fu | - |
dc.contributor.author | Peng, Cheng-Yuan | - |
dc.contributor.author | Liang, Po-Chin | - |
dc.contributor.author | Bartlett, Adam | - |
dc.contributor.author | Kok, Kenneth Y. Y. | - |
dc.contributor.author | Thng, Choon-Hua | - |
dc.contributor.author | Low, Albert Su-Chong | - |
dc.contributor.author | Goh, Anthony S. W. | - |
dc.contributor.author | Tay, Kiang Hiong | - |
dc.contributor.author | Lo, Richard H. G. | - |
dc.contributor.author | Goh, Brian K. P. | - |
dc.contributor.author | Ng, David C. E. | - |
dc.contributor.author | Lekurwale, Ganesh | - |
dc.contributor.author | Liew, Wei Ming | - |
dc.contributor.author | Gebski, Val | - |
dc.contributor.author | Mak, Kenneth S. W. | - |
dc.contributor.author | Soo, Khee Chee | - |
dc.date.accessioned | 2021-09-02T09:05:12Z | - |
dc.date.available | 2021-09-02T09:05:12Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-07-01 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/74390 | - |
dc.description.abstract | PurposeSelective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC.Patients and MethodsSIRveNIB (selective internal radiation therapy v sorafenib), an open-label, investigator-initiated, phase III trial, compared yttrium-90 (Y-90) resin microspheres RE with sorafenib 800 mg/d in patients with locally advanced HCC in a two-tailed study designed for superiority/detriment. Patients were randomly assigned 1:1 and stratified by center and presence of portal vein thrombosis. Primary end point was overall survival (OS). Efficacy analyses were performed in the intention-to-treat population and safety analyses in the treated population.ResultsA total of 360 patients were randomly assigned (RE, 182; sorafenib, 178) from 11 countries in the Asia-Pacific region. In the RE and sorafenib groups, 28.6% and 9.0%, respectively, failed to receive assigned therapy without significant cross-over to either group. Median OS was 8.8 and 10.0 months with RE and sorafenib, respectively (hazard ratio, 1.1; 95% CI, 0.9 to 1.4; P = .36). A total of 1,468 treatment-emergent adverse events (AEs) were reported (RE, 437; sorafenib, 1,031). Significantly fewer patients in the RE than sorafenib group had grade 3 AEs (36 of 130 [27.7%]) v 82 of 162 [50.6%]; P < .001). The most common grade 3 AEs were ascites (five of 130 [3.8%] v four of 162 [2.5%] patients), abdominal pain (three [2.3%] v two [1.2%] patients), anemia (zero v four [2.5%] patients), and radiation hepatitis (two [1.5%] v zero [0%] patients). Fewer patients in the RE group (27 of 130 [20.8%]) than in the sorafenib group (57 of 162 [35.2%]) had serious AEs.ConclusionIn patients with locally advanced HCC, OS did not differ significantly between RE and sorafenib. The improved toxicity profile of RE may inform treatment choice in selected patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER SOC CLINICAL ONCOLOGY | - |
dc.subject | Y-90 MICROSPHERES | - |
dc.subject | RADIOEMBOLIZATION | - |
dc.subject | RADIOTHERAPY | - |
dc.subject | MANAGEMENT | - |
dc.subject | PATTERNS | - |
dc.subject | SURVIVAL | - |
dc.subject | OUTCOMES | - |
dc.subject | SARAH | - |
dc.title | SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yun Hwan | - |
dc.identifier.doi | 10.1200/JCO.2017.76.0892 | - |
dc.identifier.scopusid | 2-s2.0-85049640422 | - |
dc.identifier.wosid | 000441233400005 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, v.36, no.19, pp.1913 - + | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.title | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.volume | 36 | - |
dc.citation.number | 19 | - |
dc.citation.startPage | 1913 | - |
dc.citation.endPage | + | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | Y-90 MICROSPHERES | - |
dc.subject.keywordPlus | RADIOEMBOLIZATION | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | PATTERNS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | SARAH | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.